Sandu Pharmaceuticals Quarterly Results for Trading Insights
In Mar 2025, Sandu Pharmaceuticals (SANDUPHQ) reported revenue ₹14 Cr and net profit ₹0 Cr — revenue -12.5% YoY. For annual financials, live price and key ratios, visit SANDUPHQ share price.
SANDUPHQ Quarterly Results — Revenue, Profit & EPS Highlights
Sandu Pharmaceuticals latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore Sandu Pharmaceuticals share price performance to track price trends across different timeframes.
- Revenue of ₹14 Cr in Mar 2025 (-22.2% vs Sept 2024, -12.5% vs Mar 2024)
- EBITDA of ₹1 Cr in Mar 2025 (+0.0% vs Sept 2024)
- Operating Margin of 3.0% in Mar 2025 (-2.0pp vs Sept 2024)
- Earnings Per Share of ₹0.34 in Mar 2025 (-82.6% vs Sept 2024)
Sandu Pharmaceuticals Quarterly Results — Revenue, EBITDA, Net Profit & EPS
SANDUPHQ quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2025 | Sept 2024 | Mar 2024 | Jun 2024 | Dec 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 14 | 18 | 16 | 17 | 18 | -22.2% | -12.5% |
| Net Profit (₹ Cr) | 0 | 1 | 1 | 0 | 1 | - | - |
| EBITDA (₹ Cr) | 1 | 1 | 1 | 0 | 1 | - | - |
| EPS (₹) | 0.34 | 1.95 | 0.62 | 0.17 | 0.57 | - | - |
| Operating Margin (%) | 3.0% | 5.0% | 4.0% | 2.0% | 5.0% | - | - |
SANDUPHQ Share Price Trend — 1-Year Movement Across Quarterly Results
Sandu Pharmaceuticals 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Browse Sandu Pharmaceuticals financial data for revenue, profit, balance sheet and cash flow data.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
SANDUPHQ vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Sandu Pharmaceuticals latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹454,122.13 Cr | 1904.8 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 168.6 |
|
Divis Laboratories
Mar 2026 |
₹174,081.02 Cr | 6757.0 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 238.7 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹161,380.94 Cr | 4768.3 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 414.3 |
|
Cipla
Mar 2026 |
₹117,800.00 Cr | 1458.2 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 212.3 |
|
Dr Reddys Laborator…
Mar 2026 |
₹114,691.88 Cr | 1374.1 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 518.5 |
All amounts in ₹ Crores